CompletedPHASE1, PHASE2NCT00081874

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Studying Acute mast cell leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Francis J. Giles, MD
UT MD Anderson Cancer Center
Intervention
RAD001(drug)
Enrollment
29 enrolled
Eligibility
All sexes
Timeline
2004 – 2006

Study locations (1)

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00081874 on ClinicalTrials.gov

Other trials for Acute mast cell leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute mast cell leukemia →

← Back to all trials